10x Genomics Announces Pricing of Upsized Public Offering
September 10 2020 - 11:16PM
10x Genomics, Inc. (NASDAQ: TXG) (the “Company”) today announced
the pricing of an upsized underwritten public offering by the
Company of its Class A common stock at a price to the public of
$110.00 per share, before underwriting discounts and commissions.
10x Genomics is offering 4,000,000 shares of its Class A common
stock, plus up to an additional 600,000 shares of its Class A
common stock that the underwriters have the right to purchase at
the public offering price, less the underwriting discounts and
commissions. All of the shares are being offered by the Company.
The offering is expected to close on September 15, 2020, subject to
customary closing conditions.
The offering is being made through an underwriting group led by
J.P. Morgan Securities LLC, BofA Securities and Cowen and Company,
LLC. Stifel and William Blair are acting as co-managers for the
offering.
Registration statements relating to these securities have been
filed with the Securities and Exchange Commission and became
effective on September 10, 2020.
This offering is being made only by means of a prospectus,
copies of which may be obtained by contacting: J.P. Morgan
Securities LLC, Attention: Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY 11717, by telephone at
1-866-803-9204 or by email at prospectus-eq_fi@jpmchase.com; BofA
Securities, NC1-004-03-43, 200 North College Street, 3rd floor,
Charlotte, NC 28255-0001, Attention: Prospectus Department, or by
email at dg.prospectus_requests@bofa.com and Cowen and Company,
LLC, c/o Broadridge Financial Solutions, Attention: Prospectus
Department, 1155 Long Island Avenue, Edgewood, NY 11717, or by
telephone at (833) 297-2926, or by email at
PostSaleManualRequests@broadridge.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
Forward-looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
as contained in Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, including with respect to the closing of the Company’s
offering. Forward-looking statements generally can be identified by
the use of forward-looking terminology such as “may,” “will,”
“should,” “expect,” “plan,” “anticipate,” “could,” “intend,”
“target,” “project” “contemplate,” “believe,” “estimate,”
“predict,” “potential” or “continue” or the negatives of these
terms or variations of them or similar terminology. These
forward-looking statements are subject to significant risks and
uncertainties, including, without limitation, risks and
uncertainties related to economic, market or business conditions
and satisfaction of customary closing conditions related to the
offering, that could cause the Company’s actual results to differ
materially from those expressed in these forward-looking
statements. The forward-looking statements in this press release
are based on information available to the Company as of the date
hereof, and the Company disclaims any obligation to update any
forward-looking statements provided to reflect any change in its
expectations or any change in events, conditions, or circumstances
on which any such statement is based, except as required by law.
These forward-looking statements should not be relied upon as
representing the Company’s views as of any date subsequent to the
date of this press release.
Contacts:
Investorsinvestors@10xgenomics.com
Mediamedia@10xgenomics.com
10x Genomics (NASDAQ:TXG)
Historical Stock Chart
From Jun 2024 to Jul 2024
10x Genomics (NASDAQ:TXG)
Historical Stock Chart
From Jul 2023 to Jul 2024